At a glance
ClinicalIndex Comparison Record- ✓Ages 21 to 50 years old
- ✓Social drinkers
- ✓Able to read English at 6th grade level or higher and complete study evaluations
- ✓Willing to abstain from drinking alcohol during the outpatient study medication treatment period
- ✕Currently seeking treatment for alcohol drinking
- ✕Current DSM-V criteria for substance use disorder other than alcohol or nicotine
- ✕Positive urine drug screen after intake for opiates, cocaine, marijuana, benzodiazepines, or barbiturates
- ✕Regular use of psychoactive drugs including anxiolytics and antidepressants
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study on the Safety and Efficacy of Mavoglurant in Alcohol Drinking
In Brief
A Phase 1 clinical trial evaluating Mavoglurant and Placebo for Alcohol Drinking. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this alcohol-interaction pilot study is to provide information on the effect of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects of 200 mg mavoglurant versus placebo on alcohol related responses. This is a between subjects double blind randomized design in which the investigators plan to run 40 subjects to obtain 28 completers.
Study Details
Timeline
Interventions
200 mg Mavoglurant
Placebo